New hope for bile duct cancer: targeted pill may prevent recurrence after standard treatment

NCT ID NCT07260175

First seen Jan 08, 2026 · Last updated Apr 24, 2026 · Updated 23 times

Summary

This study tests whether a daily pill called ivosidenib can help prevent bile duct cancer from returning in people who have already had surgery and chemotherapy. The drug targets a specific genetic change (IDH1 mutation) found in some bile duct cancers. About 40 adults with this mutation will take ivosidenib for up to a year, and researchers will track how many remain cancer-free after one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Klinikum rechts der Isar TU München

    RECRUITING

    München, 81675, Germany

    Contact

  • Krankenhaus Nordwest

    RECRUITING

    Frankfurt, 60488, Germany

    Contact

  • Uniklinik RWTH Aachen

    RECRUITING

    Aachen, 52074, Germany

    Contact

  • Uniklinikum Jena

    RECRUITING

    Jena, 7747, Germany

    Contact

  • Universitätsklinikum Bonn

    RECRUITING

    Bonn, 53127, Germany

    Contact

  • Universitätsklinikum Frankfurt

    RECRUITING

    Frankfurt, 60590, Germany

    Contact

  • Universitätsklinikum Mannheim

    RECRUITING

    Mannheim, 68167, Germany

    Contact

  • Universitätsmedizin Göttingen

    RECRUITING

    Göttingen, 37099, Germany

    Contact

Conditions

Explore the condition pages connected to this study.